Background: Neoadjuvant chemoradiotherapy for oesophageal cancer significantly improves overall survival but is associated with severe post-operative complications. Proton beam therapy may reduce these toxicities by sparing normal tissues compared with standard radiotherapy. ProtOeus is a proposed randomised phase II study of neoadjuvant chemoradiotherapy in oesophageal cancer that compares proton beam therapy to standard radiotherapy techniques. As proton beam therapy services are often centralised in academic centres in major cities, proton beam therapy trials raise distinct challenges including patient acceptance of travelling for proton beam therapy, coordination of treatments with local centres and ensuring equity of access for patients.
Methods: Focus groups were held early in the trial development process to establish patients' views on the trial proposal. Topics discussed include perception of proton beam therapy, patient acceptability of the trial pathway and design, patient-facing materials, and common clinical scenarios. Focus groups were led by the investigators and facilitated by patient involvement teams from the institutions who are involved in this research. Responses for each topic were analysed, and fed back to the trial's development group.
Results: Three focus groups were held in separate locations in the UK (Manchester, Cardiff, Wigan). Proton beam therapy was perceived as superior to standard radiotherapy making the trial attractive. Patients felt strongly that travel costs should be reimbursed to ensure equity of access to proton beam therapy. They were very supportive of a shorter treatment schedule and felt that toxicity reduction was the most important endpoint.
Discussion And Conclusions: Incorporating patient views early in the trial development process resulted in significant trial design refinements including travel/accommodation provisions, choice of primary endpoint, randomisation ratio and fractionation schedule. Focus groups are a reproducible and efficient method of incorporating the patient and public voice into research.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s40271-020-00487-8 | DOI Listing |
J Radiat Res
December 2024
Section of Radiation Safety and Quality Assurance, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
We assessed the effect of beam size on plan robustness for intensity-modulated proton therapy (IMPT) of head and neck cancer (HNC) and compared the plan quality including robustness with that of intensity-modulated radiation therapy (IMRT). IMPT plans were generated for six HNC patients using six beam sizes (air-sigma 3-17 mm at isocenter for a 70-230 MeV) and two optimization methods for planning target volume-based non-robust optimization (NRO) and clinical target volume (CTV)-based robust optimization (RO). Worst-case dosimetric parameters and plan robustness for CTV and organs-at-risk (OARs) were assessed under different scenarios, assuming a ± 1-5 mm setup error and a ± 3% range error.
View Article and Find Full Text PDFRev Sci Instrum
December 2024
Plasmaphysics Department, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstrasse 1, 64291 Darmstadt, Germany.
A new high energy proton radiography facility PRIOR-II (Proton Microscope for FAIR) has been designed, constructed, and successfully commissioned at the GSI Helmholtzzentrum für Schwerionenforschung (Darmstadt, Germany) pushing the technical boundaries of charged particle radiography with normal conducting magnets to the limits. The setup is foreseen to become a new and powerful user facility for carrying out fundamental science experiments in the fields of plasma and shock wave physics, material science, and medical physics. It will help address several unsolved scientific challenges, which require high-speed and precise non-invasive diagnostic methods capable of probing matter with up to 100 g/cm2 areal density.
View Article and Find Full Text PDFAppl Radiat Isot
December 2024
Institute of Nuclear Techniques of Budapest University of Technology and Economics, Műegyetem Rkp 9, 1111, Budapest, Hungary.
This study presents a compact accelerator-driven neutron source design with a thermal neutron port and an epithermal neutron port for Boron Neutron Capture Therapy (BNCT), based on 10 mA 2.5 MeV protons bombarding on a 100 μm thick disc-shaped Li target with a diameter of 10 cm. The moderator consists of 2 parts, the epithermal neutron moderator and the thermal neutron moderator.
View Article and Find Full Text PDFMed Phys
December 2024
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Background: Rapid planning is of tremendous value in proton pencil beam scanning (PBS) therapy in overcoming range uncertainty. However, the dose calculation of the dose influence matrix (D) in robust PBS plan optimization is time-consuming and requires substantial acceleration to enhance efficiency.
Purpose: To accelerate the D calculations in PBS therapy, we developed an AI-D engine integrated into our in-house treatment planning system (TPS).
J Appl Clin Med Phys
December 2024
Department of Radiation Oncology, Lynn Cancer Institute, Boca Raton Regional Hospital, Baptist Health South Florida, Boca Raton, Florida, USA.
Purpose: A novel proton beam delivery method known as DynamicARC spot scanning has been introduced. The current study aims to determine whether the partial proton arc technique, in conjunction with DynamicARC pencil beam scanning (PBS), can meet clinical acceptance criteria for bilateral head and neck cancer (HNC) and provide an alternative to full proton arc and traditional intensity-modulated proton therapy (IMPT).
Method: The study retrospectively included anonymized CT datasets from ten patients with bilateral HNC, all of whom had previously received photon treatment.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!